Premium
Danazol therapy in cyclic acquired amegakaryocytic thrombocytopenic purpura: A case report
Author(s) -
Kashyap Rajesh,
Choudhry V.P.,
Pati H.P.
Publication year - 1999
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/(sici)1096-8652(199903)60:3<225::aid-ajh10>3.0.co;2-s
Subject(s) - danazol , thrombocytopenic purpura , medicine , platelet , pathogenesis , dermatology , endometriosis
Cyclic acquired amegakaryocytic thrombocytopenic purpura (AATP) is a rare disorder characterized by periodic fluctuations in the platelet counts due to a defect in the platelet production. We describe a 42‐year‐old female with cyclic AATP, in whom the cyclic fluctuations in the platelet counts ceased with danazol therapy. The pathogenesis of the disease and the possible mechanisms of danazol action have been reviewed. Am. J. Hematol. 60:225–228, 1999. © 1999 Wiley‐Liss, Inc.